In summary, an OV encoding OX40L and IL12 is a potent tumor-specific oncolytic immunotherapy that transforms tumor cells into aAPCs in situ and sensitizes solid tumors to TIL therapy. This evidence concerns the gene TNFSF4 and neoplasm.